Online inquiry

IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1383MR)

This product GTTS-WQ1383MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1A&IL1B gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000575.5; NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3552; 3553
UniProt ID P01583; P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1383MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12536MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ4433MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ7837MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ4981MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ10084MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ10860MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ3144MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ15233MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TAK-079
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW